Ryaltris, which was developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate). Each unit of the ...

approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris. According to Glenmark, the drug is for rhinitis in adults and paediatric patients 12 years of age and ...

Glenmark Pharmaceuticals on Friday said its subsidiary has received approval from the US health regulator to market Ryaltris, a nasal spray for the treatment of seasonal allergic rhinitis.